reposit
drug
alreadi
approv
regulatori
agenc
indic
emerg
altern
develop
new
antimicrobi
therapi
reposit
process
involv
lower
risk
cost
de
novo
develop
novel
antimicrobi
drug
current
infect
adenoviru
show
steadi
increment
high
clinic
impact
immunosuppress
immunocompet
patient
lack
safe
efficaci
drug
treat
infect
support
search
new
antivir
drug
evalu
antiadenoviru
activ
niclosanid
oxyclozanid
rafoxanid
three
salicylanilid
anthelmint
drug
also
carri
cytotox
evalu
partial
character
mechan
action
drug
salicylanilid
anthelmint
drug
show
signific
antiadenoviru
activ
low
micromolar
concentr
littl
cytotox
moreov
mechanist
assay
suggest
differ
way
drug
exert
antiadenoviru
activ
niclosamid
rafoxanid
target
transport
hadv
particl
endosom
nuclear
envelop
whilst
oxyclozanid
specif
target
adenoviru
immedi
earli
gene
transcript
data
suggest
studi
salicylanilid
anthelmint
drug
could
suitabl
clinic
evalu
develop
new
antivir
drug
treat
infect
adenoviru
immunosuppress
patient
immunocompet
individu
communityacquir
pneumonia
antiadenoviru
activ
salicylanilid
anthelmint
drug
initi
studi
determin
inhibitori
concentr
three
anthelmint
drug
hadv
plaqu
assay
measur
percentag
plaqu
format
inhibit
compar
control
cell
infect
absenc
drug
three
salicylanilid
anthelmint
drug
show
dosedepend
antihadv
activ
inhibit
plaqu
format
nic
oxi
raf
respect
fig
b
ic
valu
three
anthelmint
drug
summar
tabl
also
evalu
whether
salicylanilid
anthelmint
drug
abl
inhibit
viru
product
use
yield
reduct
assay
treatment
nic
oxi
raf
associ
overal
reduct
viru
yield
tabl
assay
measur
antivir
activ
three
anthelmint
drug
function
moi
inhibit
invers
proport
number
input
particl
fig
also
inhibitori
high
moi
relationship
number
infect
hadv
particl
drug
concentr
less
mark
expect
cellular
cytotox
salicylanilid
drug
also
analyz
cc
valu
molecul
case
significantli
higher
ic
concentr
requir
inhibit
antivir
activ
mechanist
assay
cell
tabl
cell
nic
oxi
raf
respect
step
hadv
replic
cycl
first
step
toward
identifi
specif
step
hadv
replic
cycl
inhibit
drug
measur
time
depend
three
anthelmint
drug
addit
abil
block
hadv
infect
previou
report
show
biochem
hadv
viral
particl
intern
within
min
bind
reach
nuclear
pore
min
result
demonstr
nic
oxi
raf
exhibit
timedepend
decreas
inhibitori
activ
fig
show
high
inhibit
hadv
infect
ad
begin
min
incub
min
ad
immedi
prior
warm
min
min
howev
drug
ad
min
oxi
still
show
signific
inhibit
higher
lost
nic
raf
fig
support
find
western
blot
hadv
protein
run
h
post
infect
result
obtain
show
significantli
lower
express
protein
sampl
treat
nic
raf
compar
oxi
fig
impact
hadv
genom
access
nucleu
assay
evalu
impact
salicylanilid
anthelmint
drug
hadv
endosom
escap
bind
intern
hadv
viral
particl
exposur
protein
vi
insid
endosom
trigger
endosomolysi
partial
decapsid
hadv
escap
cytosol
transport
nuclear
pore
complex
nuclear
membran
microtubul
network
use
function
assay
compris
hadvmedi
codeliveri
cell
marker
abil
salicylanilid
drug
alter
virusmedi
endosomolysi
signific
differ
id
inhibitori
dose
hadvmedi
endosom
penetr
detect
presenc
salicylanilid
drug
fig
dmso
neg
control
contrast
control
viru
endosom
penetrationdefect
mutant
exhibit
signific
increas
id
compar
dmso
control
fig
viral
particl
leav
endosom
transport
nuclear
pore
complex
hadv
genom
import
nucleu
hypothes
drug
examin
block
step
hadv
entri
expect
nic
number
genom
reach
nucleu
would
lower
next
evalu
abil
salicylanilid
drug
block
hadv
genom
access
nucleu
quantif
hadv
genom
isol
nucleu
reflect
fig
nic
raf
show
signific
block
access
hadv
genom
nucleu
fig
dna
copi
number
cellular
gene
gapdh
also
evalu
nucleu
cytoplasm
control
puriti
nuclear
isol
data
shown
sinc
result
indic
nic
raf
hinder
access
hadv
genom
nucleu
oxi
resolv
determin
anthelmint
drug
affect
later
step
hadv
life
cycl
impact
hadv
replic
next
step
examin
effect
oxi
upon
effici
hadv
dna
replic
use
quantit
realtim
pcr
qpcr
cell
infect
hadv
incub
h
unbound
virion
washedout
cell
cultur
incub
h
hadv
dna
extract
point
limit
interfer
caus
subsequ
round
infect
occur
h
postinfect
use
quantit
pcr
quantifi
singl
round
infect
synthesi
new
hadv
dna
copi
measur
dna
replic
effici
presenc
oxi
significantli
inhibit
dna
replic
p
dunnett
multipl
comparison
test
whilst
quantif
dna
copi
gapdh
gene
show
signific
effect
fig
reduct
hadv
dna
copi
number
nucleu
presenc
oxi
implic
two
altern
mechan
action
oxi
could
inhibit
hadv
dna
replic
interf
protein
requir
process
like
hadv
dna
polymeras
dna
bind
protein
dbp
termin
protein
tp
altern
ii
oxi
could
impact
transcript
hadv
immedi
earli
gene
key
step
dna
replic
assay
inhibit
hadv
mrna
transcript
infect
cell
presenc
oxi
h
infect
quantifi
rna
copi
number
gene
use
quantit
revers
transcript
rtpcr
shown
fig
oxi
exert
signific
decreas
mrna
copi
number
compar
control
treat
dmso
base
previou
work
piperazin
deriv
nucleotid
nucleosid
analogu
show
antivir
activ
multipl
dsdna
viru
includ
cytomegaloviru
hcmv
hadv
evalu
inhibitori
activ
nic
oxi
raf
hcmv
dna
replic
presenc
anthelmint
drug
gener
signific
reduct
quantif
total
hcmv
dna
h
infect
cell
fig
oxi
show
decreas
whilst
nic
raf
reach
decreas
respect
hcmv
dna
replic
show
signific
differ
sampl
quantif
gapdh
gene
data
shown
salicylanilid
anthelmint
drug
combin
improv
antivir
activ
sinc
found
differ
mechan
action
three
drug
hypothes
combin
significantli
improv
antivir
activ
evalu
hypothesi
conduct
combin
studi
base
choutalalay
method
drug
combin
use
calcusyn
softwar
constant
ration
combin
select
base
ic
valu
drug
data
combin
show
good
conform
mass
action
law
r
tabl
combin
classifi
synergist
tabl
nic
raf
ratio
combin
ic
ic
level
inhibit
classifi
synerg
ic
level
strong
synerg
tabl
final
combin
raf
oxi
ratio
classifi
synerg
level
inhibit
tabl
aim
studi
evalu
antihadv
activ
nic
salicylanilid
anthelmint
drug
human
use
set
basi
experiment
clinic
develop
potenti
new
treatment
hadv
infect
moreov
includ
evalu
two
chlorin
salicylanilid
anthelmint
deriv
approv
anim
use
oxi
raf
close
relat
structur
mechan
action
nic
wellknown
drug
act
uncoupl
oxid
phosphoryl
involv
dissip
membran
potenti
case
nic
jurgeitr
et
al
previous
demonstr
antivir
mechan
action
specif
associ
neutral
endosom
ph
thu
show
broad
antivir
activ
phdepend
virus
although
hadv
endosom
escap
exclus
depend
ph
low
ph
proven
associ
endosom
escap
hadv
premis
initi
assum
probabl
common
antihadv
mechan
action
three
drug
decid
character
antihadv
activ
previou
step
evalu
safeti
efficaci
syrian
hamster
model
hadv
infect
show
nic
oxi
raf
exert
signific
antihadv
antihcmv
activ
low
concentr
put
data
perspect
noteworthi
report
ic
valu
cidofovir
drug
choic
treatment
hadv
infect
higher
shown
three
salicylanilid
drug
addit
follow
methodolog
ic
valu
cidofovir
significantli
higher
valu
obtain
three
salicylanilid
drug
mechan
action
data
obtain
work
demonstr
one
three
closelyrel
drug
share
expect
mode
action
confirm
work
nic
novelti
raf
act
decreas
number
hadv
genom
associ
host
nucleu
howev
demonstr
physiolog
assay
use
ribotoxin
nic
raf
may
act
later
step
hadv
endosom
escap
unlik
nic
raf
oxi
inhibit
access
hadv
genom
nucleu
observ
confirm
timecours
assay
found
nic
raf
inhibit
occur
earliest
time
hadv
replic
cycl
oxi
well
westernblot
assay
hpi
show
higher
inhibit
gene
express
nic
raf
shown
result
high
inhibit
hadv
dna
replic
gener
oxi
may
consequ
previou
signific
inhibit
gene
transcript
support
result
show
clear
inhibit
transcript
hpi
quantit
realtim
pcr
westernblot
well
known
prior
hadv
dna
replic
transcript
cellular
rna
polymeras
ii
take
place
promot
protein
promot
transcript
need
subsequ
express
earli
gene
differ
promot
well
dna
replic
probabl
observ
signific
inhibit
hadv
dna
replic
exist
differ
mechan
antivir
activ
three
drug
support
signific
combinatori
index
valu
obtain
use
calcusyn
softwar
drug
combin
tabl
three
anthelmint
drug
show
moder
synergist
strong
synergist
activ
combin
pair
especi
strong
level
inhibit
evalu
nicoxi
combin
likewis
use
combin
three
show
strong
synergist
activ
level
inhibit
evalu
reposit
drug
diseas
differ
approv
valuabl
altern
drug
discoveri
develop
sinc
reduc
significantli
high
cost
timeconsumpt
develop
new
drug
case
nic
anthelmint
drug
numer
report
support
repurpos
anticanc
drug
due
cancer
inhibitori
properti
nic
fdaapprov
drug
use
mani
year
treat
helminth
infect
human
previous
demonstr
antivir
potenti
differ
virus
japanes
enceph
flaviviru
zika
viru
coronaviru
human
rhinoviru
influenza
viru
rat
nic
known
exert
low
vivo
toxic
median
lethal
dose
ld
mgkg
bodi
weight
gener
peak
serum
concentr
depend
dose
administr
rout
healthi
human
oral
treat
mg
nic
per
person
sign
intox
seen
drug
remain
detect
day
peak
serum
concentr
report
shown
result
serum
concentr
enough
reach
ic
hadv
tabl
oxi
raf
fdaapprov
drug
veterinari
use
treat
helminth
infect
oxi
high
serum
concentr
rang
report
sheep
goat
singl
oral
dose
mgkg
case
raf
intraven
singl
dose
mgkg
goat
gener
serum
concentr
rang
regist
h
h
respect
singl
oral
dose
mgkg
also
goat
maximum
serum
concentr
obtain
h
h
respect
case
oxi
raf
serum
concentr
significantli
higher
ic
hadv
tabl
toxic
ld
raf
report
higher
mgkg
bodi
weight
rat
oxi
accord
european
medicin
agenc
emea
ld
would
higher
mgkg
bodi
weight
also
rat
find
show
signific
antihadv
activ
three
salicylanilid
drug
target
differ
step
hadv
life
cycl
nic
raf
would
mainli
block
hadv
infect
point
endosom
escap
dna
releas
nucleu
whilst
activ
oxi
would
specif
target
hadv
immedi
earli
gene
transcript
find
support
evalu
three
drug
syrian
hamster
model
hadv
infect
evalu
efficaci
safeti
pharmacokinet
profil
salicylanilid
drug
show
low
water
solubl
oral
bioavail
may
hamper
clinic
develop
situat
gener
deriv
salicylanilid
drug
base
ration
chemic
approach
may
improv
poor
pharmacokinet
increas
solubl
bioavail
potenti
clinic
candid
antivir
therapi
wildtyp
speci
c
speci
b
speci
human
cytomegaloviru
hcmv
obtain
atcc
use
studi
replicationdefect
virus
cmv
promoterdriven
enhanc
green
fluoresc
protein
egfp
report
gene
cassett
place
region
hadv
propag
cell
isol
cellular
lysat
cesium
chlorid
cscl
densiti
gradient
combin
ultracentrifug
viru
concentr
mg
ml
calcul
use
biorad
protein
assay
biorad
laboratori
convert
viru
particlesml
vpml
use
vpmg
cytotox
assay
nic
oxi
raf
cytotox
evalu
use
alamar
blue
cell
viabil
assay
invitrogen
accord
manufactur
instruct
activ
divid
cell
incub
salicylanilid
anthelmint
drug
h
incub
alamar
blue
reagent
ad
cell
alamar
blue
reagent
cultur
medium
extra
h
cytotox
concentr
cc
calcul
previous
report
cheng
et
al
select
index
si
calcul
ratio
cc
ic
ic
defin
concentr
anthelmint
drug
inhibit
hadv
infect
hadv
plaqu
assay
anthelmint
drug
test
doserespons
assay
use
moi
vpcell
drug
concentr
rang
plaqu
assay
briefli
densiti
cell
per
well
seed
plate
confluenc
infect
vpcell
rock
h
incub
well
washedout
pb
cell
care
overlaid
mlwell
equal
part
watervol
difco
agar
nobl
becton
dickinson
co
spark
md
emem
minimum
essenti
medium
eagl
biowhittak
supplement
penicillinstreptomycin
lglutamin
fb
mixtur
also
contain
drug
concentr
rang
incub
day
viru
plaqu
scan
typhoon
imag
ge
healthcar
life
scienc
quantifi
imagej
determin
time
cours
three
anthelmint
drugsmedi
inhibit
parallel
sampl
wildtyp
incub
without
nic
raf
oxi
complet
dmem
h
viru
vpcell
ad
cell
cellswel
plate
incub
anthelmint
drug
ad
indic
time
point
min
incub
incub
co
h
dna
purifi
cell
lysat
use
qiaamp
dna
mini
kit
qiagen
valencia
ca
follow
manufactur
instruct
dna
quantifi
quantit
pcr
follow
describ
protocol
analysi
anthelmint
drug
combin
softwar
packet
calcusyn
biosoft
ferguson
mo
usa
compar
drug
concentr
requir
combin
gener
given
effect
drug
concentr
would
need
individu
achiev
effect
use
assay
plaqu
doserespons
assay
carri
use
possibl
combin
three
drug
start
twice
ic
obtain
previous
compound
ratio
concentr
calcusyn
softwar
interpol
drug
concentr
need
combin
select
ratio
gener
effect
inhibit
compar
combin
drug
concentr
concentr
three
drug
individu
doserespons
curv
requir
achiev
inhibit
combin
effect
three
drug
report
combin
index
ci
valu
quantit
estim
pharmacolog
interact
use
potenc
ic
shape
doserespons
curv
individu
drug
combin
ci
valu
interpret
accord
matthew
et
al
nuclearassoci
hadv
genom
nuclear
access
hadv
genom
evalu
realtim
pcr
follow
previous
describ
protocol
modif
briefli
cell
plate
infect
wildtyp
moi
vpcell
presenc
nic
oxi
raf
volum
dmso
neg
control
fortyf
minut
infect
cell
trypsin
collect
wash
twice
pb
nuclear
cytoplasm
fraction
separ
use
hypoton
buffer
solut
consist
mm
trishcl
ph
mm
nacl
mm
mgcl
cell
pellet
resuspend
hypoton
buffer
incub
min
ad
sampl
vortex
homogen
centrifug
min
g
hadv
dna
isol
nuclear
pellet
cytoplasm
fraction
supernat
use
qiaamp
dna
mini
kit
qiagen
valencia
ca
measur
endosom
disrupt
hadvmedi
ribotoxin
deliveri
assay
perform
previous
describ
hadv
dna
mrna
quantif
realtim
pcr
dna
quantif
cell
well
plate
infect
vpcell
wildtyp
incub
h
complet
dmem
excess
viru
washedout
medium
replac
complet
dmem
contain
either
anthelmint
drug
volum
dmso
neg
control
sampl
done
triplic
h
incub
co
dna
purifi
cell
lysat
use
qiaamp
dna
mini
kit
qiagen
valencia
ca
follow
manufactur
instruct
taqman
primer
probe
pcr
condit
like
previous
report
evalu
rna
express
condit
infect
appli
dna
quantif
use
six
hour
infect
rna
purifi
mircuri
rna
isol
kit
exiqon
inc
follow
manufactur
instruct
quantif
rna
copi
number
perform
use
primer
condit
previous
report
human
dehydrogenas
gapdh
gene
use
intern
control
primer
probe
condit
appli
gapdh
previous
report
rivera
et
al
quantif
gene
fragment
hexon
gapdh
clone
pgemt
easi
vector
promega
known
concentr
vector
use
gener
standard
curv
experi
assay
perform
thermal
cycler
apparatu
biorad
burst
assay
use
assay
effect
three
anthelmint
drug
viru
product
cell
infect
wildtyp
wildtyp
wildtyp
presenc
absenc
nic
oxi
raf
incub
h
cell
harvest
subject
three
round
freezethaw
serial
dilut
clarifi
lysat
titrat
cell
tcid
valu
calcul
use
previous
report
endpoint
dilut
method
test
antihcmv
activ
anthelmint
drug
cell
seed
plate
cellswel
infect
hcmv
moi
vp
cell
incub
complet
dmem
presenc
nic
case
oxi
raf
volum
dmso
triplic
cell
incub
h
co
hcmv
dna
purifi
cell
lysat
use
qiaamp
dna
mini
kit
qiagen
valencia
ca
follow
manufactur
instruct
realtim
pcr
primer
mixtur
protocol
previous
report
statist
analys
statist
analys
carri
use
graphpad
prism
suit
data
present
mean
triplic
sampl
standard
deviat
sd
unless
otherwis
indic
p
consid
statist
signific
